Nivolumab-associated hypopituitarism in a 61-year-old woman with metastatic triple-negative breast
{{output}}
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of cancer, enhancing response rates and survival outcomes. However, immune-related adverse events (irAEs), which can affect any organ or system, can limit their use. We report a rare ... ...
